- Research article
- Open Access
Expression profile analysis of the inflammatory response regulated by hepatocyte nuclear factor 4α
© Wang et al; licensee BioMed Central Ltd. 2011
- Received: 1 March 2010
- Accepted: 25 February 2011
- Published: 25 February 2011
Hepatocyte nuclear factor 4α (HNF4α), a liver-specific transcription factor, plays a significant role in liver-specific functions. However, its functions are poorly understood in the regulation of the inflammatory response. In order to obtain a genomic view of HNF4α in this context, microarray analysis was used to probe the expression profile of an inflammatory response induced by cytokine stimulation in a model of HNF4α knock-down in HepG2 cells.
The expression of over five thousand genes in HepG2 cells is significantly changed with the dramatic reduction of HNF4α concentration compared to the cells with native levels of HNF4α. Over two thirds (71%) of genes that exhibit differential expression in response to cytokine treatment also reveal differential expression in response to HNF4α knock-down. In addition, we found that a number of HNF4α target genes may be indirectly mediated by an ETS-domain transcription factor ELK1, a nuclear target of mitogen-activated protein kinase (MAPK).
The results indicate that HNF4α has an extensive impact on the regulation of a large number of the liver-specific genes. HNF4α may play a role in regulating the cytokine-induced inflammatory response. This study presents a novel function for HNF4α, acting not only as a global player in many cellular processes, but also as one of the components of inflammatory response in the liver.
- Gene Ontology
- HepG2 Cell
- Acute Phase Response
- Cytokine Treatment
- Hepatic Gene Expression
Hepatocyte nuclear factor 4α (HNF4α) is a highly conserved member of the nuclear receptor superfamily. It is highly expressed in liver, kidney, intestine, and pancreas in mammals. The active form of HNF4α is a homodimer which recognizes a direct repeat (DR) of the AGGTCA motif separated by 1 nucleotide (DR1) as a binding site. HNF4α exerts direct transcriptional effects on target genes, and it also works indirectly via the positive regulation and negative regulation of other liver-enriched transcription factors, each of which regulates numerous downstream targets [1, 2]. In contrast to the liver-enriched transcription factors HNF1α, HNF3α, HNF6, and CAAT/enhancer-binding protein (C/EBP)α, which when disrupted in the mouse genome the mice are viable but show specific effects on hepatocyte differentiation, metabolic function, and gene expression [3–6], disruption of the mouse HNF4a gene is embryonic lethal . Studies with HNF4α deficient mice  have established the critical role of this factor in regulating diverse liver functions, including glucose, fatty acid and cholesterol homeostasis, bile acid and urea biosynthesis [9–11]. Defects in HNF4α function have been linked to the human disease maturity onset diabetes of the young 1(MODY1) that results from haploinsufficiency of HNF4a gene . The pivotal role of HNF4α in the maintenance of the differentiated hepatic phenotype is highlighted by the exceptionally high number of potential target genes revealed by genome-scale target search studies. Binding sites for HNF4α in genes expressed in the liver occur more frequently than those of other liver-enriched transcription factors , supporting the idea that HNF4α is a global regulator of liver gene expression.
Diverse signaling pathways regulate the transcription of hepatocyte-specific genes. For example, trauma or infection results in the release of proinflammatory cytokines, e.g., interleukin (IL)-6, IL-1, and tumor necrosis factor-α (TNF-α). The release of these cytokines has long been known to stimulate the acute phase response (APR) and rapidly alters rates of synthesis of a group of plasma proteins known as acute phase proteins (APPs) . APPs are an established diagnostic tool as early indicators of inflammation and disease. Many APPs play beneficial roles in mediating the complex inflammatory response and seeking to restore homeostasis, but prolonged exposure to acute phase conditions has been correlated with inflammatory syndromes such as sepsis and multiple organ failure [15, 16]. An understanding of the molecular events that are involved in mediating the response to external stresses can lead to the development of therapeutic strategies for preventing the progression of the APR to the chronic inflammatory states, while preserving its protective effects.
APP gene expression is regulated at the level of transcription. Transcriptional activation is mediated by a number of transcription factors. Beyond the well-known nuclear factor-κB, (NF-κB) and signal transducer and activator of transcription (STAT) family members, HNF4α has been shown to be involved in the regulation of liver-specific genes, including acute phase genes [17, 18]. It has been reported that in several injury models, injury leads to significant changes in binding activities of several liver-enriched transcription factors, including HNF4α [18–20]. However, the functional analysis of HNF4α regulated-APR genes so far has mainly relied on the description of the expression level of a few selected genes . To achieve a global view of HNF4α during the APR, we used microarray analysis to evaluate the expression profile in HepG2 cell, a human hepatoma cell line. This cell line is similar to hepatocytes in terms of biologic responsiveness [22–24] and is widely used as a model system for studying the regulation of acute phase protein synthesis in human liver [25–27]. In this study, HepG2 cells were treated with either HNF4α short hairpin RNA (shRNA) or cytokines (IL-6, IL-1β, TNF-α) alone, or in combination of the two treatments. Our results demonstrate that HNF4α is an important regulator in liver gene expression. The highly significant overlap of genes sensitive to HNF4α knock-down and cytokine treatment suggests that HNF4α may be involved in the regulation of the liver's inflammatory response. Our data also show that HNF4α may mediate a certain amount of genes indirectly via the ETS-domain transcription factor ELK1, a mitogen-activated protein kinase (MAPK)-responsive transcription factor [28, 29], which is a previous undefined mechanism for HNF4α regulation.
Knock-down endogenous HNF4α in HepG2 cells
HNF4α acts as a global regulator of liver-specific gene expression
Given that HNF4α is a central mediator in hepatocyte-specific gene expression and liver function, it is important to identify the full spectrum of genes impacted by the loss of HNF4α. To reach this end, microarray analysis was performed to probe differences in gene expression between the control and HNF4α knock-down HepG2 cells. Because we are particularly interested in how HNF4α alters global gene expression patterns during the inflammatory response, we also examined gene expression in response to the inflammatory response induced by cytokine treatment.
Genes exhibiting altered expression by the treatment with HNF4α shRNA alone and in combination with cytokines.
HNF4 shRNA only2
FDR < 0.01
The observation that a large number of liver specific genes are affected by HNF4α is consistent with the recent work of Odom et al., in which the authors demonstrated that HNF4α binds the promoters of 12% of genes in human liver cells, whereas HNF1α binds the promoters of only 1.6% of genes using chromatin immunoprecipitation-chip (ChIP-chip). In order to determine what fraction of genes that showed differential expression in response to HNF4α knock-down is likely to be bound by HNF4α, we compared our microarray expression data to the ChIP-chip data reported by Odom et al. Only those genes in the Odom's data for which there were probesets on our microarray were considered. We found that 54% (659 of 1,219) of the genes bound by HNF4α detected by ChIP-chip also showed differential expression in response to HNF4α knock-down on our microarray. A Fisher-Exact test was used to test whether the fraction of genes in the Odom et al. data that are differentially expressed in response to HNF4α knock-down is significantly greater than the fraction of genes probed on our microarray that exhibit HNF4α-dependent expression, resulting in a highly significant p-value of p = 2.9 × 10-33. A similar analysis determined that 13% (659/5,173, p = 2.8 × 10-17) of those genes that exhibit differential expression in response to HNF4α knock-down were reported by Odom et al. to be bound by HNF4α. These results suggest that a substantial fraction of HNF4α-sensitive genes may be indirect targets of HNF4α. However, the differences seen might also be caused by the significant differences in the experimental methods used such as the data from ChIP-chip were derived from human hepatocytes, while our experiment was performed on HepG2 cells.
Majority of genes affected by cytokines are also affected by HNF4α knock-down
Genes exhibiting altered expression by the treatment with cytokines alone and in combination with HNF4α shRNA.
FDR < 0.01
More interestingly, we found that majority of those genes that exhibit differential expressions in response to cytokine treatment also reveal differential expression in response to HNF4α knock-down. Of the 2,202 probesets found to be responsive to cytokine treatment, 1,567 (71%) of them also show altered expression in response to knock-down of HNF4α, while only 635 probesets are not influenced by HNF4α knock-down (Table 2). The p-value for this level of over-representation, calculated using a Fisher Exact test, is 1.8 × 10-207. Some of these probesets are altered independently by cytokine treatment and reduction in HNF4α levels (1,065 probesets; Category C), while others show a pattern of expression where the effect of cytokine treatment and reduction in HNF4α levels is interdependent (502 probesets; Category D). When more stringent criteria were used for filtering our data, and only those probesets in response to cytokine treatment and/or HNF4α knock-down that change expression by more than two fold were chosen, we found that an even greater percentage (519/597, 87%) of probesets regulated by cytokines are also regulated by HNF4α (Table 2). This over-representation suggests that HNF4α may play a significant role in orchestrating the inflammatory response in hepatic gene expression.
Although there is significant overlap between those probesets regulated by cytokines and those regulated by HNF4α knock-down (Category C and D), the expression patterns in response to these two treatments are varied. For some probesets the response to HNF4α knock-down are in the same direction as cytokine treatment (99 probesets, clusters 4 and 7 in the interactive category D, Figure 2D). This group of genes may represent a direct linkage of HNF4α with the injury response and will serve as interesting targets for further study of the complex role of HNF4α in the response to injury. For other genes the effect of each treatment is in opposition to each other (144 probesets, clusters 3 and 5 in Category D, Figure 2D). These diverse regulatory patterns observed suggest that the effects of HNF4α knock-down as that of cytokine treatment are pleiotropic in nature affecting transcription events at basic levels allowing individual gene responses to be highly variable but none the less altered.
Previous work by our lab has demonstrated that HNF4α binding activities are significantly reduced in a burn injury mouse model and a cytokine-induced APR cell culture model [18, 21]. We have shown, utilizing the cell culture model, that the decrease in HNF4α binding activity also affects HNF4α's ability to transactivate target genes . The injury induced decrease in HNF4α binding may affect cellular transcription by simply decreasing the amount of effective HNF4α available for binding. Our ability to efficiently decrease HNF4α concentration utilizing RNA interference technique may mimic this decrease in HNF4α binding ability isolating this aspect of HNF4α's role in the injury response.
Genes annotated as participating in inflammatory response exhibit distinct expression patterns
In order to further explore the function of HNF4α in the inflammatory response, a set of 170 genes annotated as playing a key role in inflammatory response was obtained from Gene ontology (GO) http://geneontology.org. These inflammatory response genes are highly enriched in the set of probesets up-regulated by cytokines (p = 3.5 × 10-3, 334% above background), but not in those probesets down-regulated after cytokine treatment. Slightly more inflammatory response genes are up-regulated in response to HNF4α knock-down than those that are down-regulated, but the difference is not statistically significant (p > 0.05).
HNF4α may regulate a large number of targets via the ETS family of transcription factors
To gain insight into the complex transcriptional networks that regulate hepatic gene expression, the promoter region (-1 kb to +0.5 kb relative to the transcription start site, TSS) of genes was extracted, and potential transcription factor binding sites were identified using Clover . By extensive search of the genes found to be differentially expressed as a function of HNF4α knock-down, we found that the HNF4α motif is not statistically enriched in the promoters of genes whose expression changes in response to HNF4α knock-down relative to promoters chosen randomly from throughout the genome (p > 0.05). There are several possible reasons for this observation. Firstly, HNF4α binding sites may be located far up-stream or down-stream of the TSS, although the results still remain the same when we extended our search up to 5 kb up-stream and 2.5 kb down-stream of the TSS. Secondly, there might be a fraction of sites that bind HNF4α but differ from the established consensus. Thirdly, HNF4α may interact with proximal promoters through formation of enhancer/promoter loops with HNF4α binding to distal regulatory element . Yet another possibility is that HNF4α might act as a cofactor, interacting with other transcription factors and not directly bind to DNA.
The transcription factor ELK1 is of particular interest as this protein is a nuclear target of extracellular-regulated kinases (ERKs) and plays a pivotal role in immediate early gene induction by external stimuli [28, 29]. It has been known that HNF4α expression is modulated by MAP kinase signaling [37, 38]. Li et al. reported that ELK1 is involved in the inflammatory response via stimulation of chemokine by thrombin. These observations suggest that the relationship between ELK1 and HNF4α may be especially relevant to understanding the role of HNF4α in regulating the inflammatory response.
HNF4α is a major regulator of hepatic gene expression. The complex physiological effects of HNF4α on the regulation and maintenance of hepatic phenotype are likely involved both directly and indirectly in a systemic response such as that seen in a response to injury or inflammation. Our microarray data are consistent with a broad effect of HNF4α on liver functions, and more importantly, the microarray analysis provides a genomic view for the role of HNF4α in the inflammation response, which greatly extends the observations from both animal- and cell culture-injury models. However, more experimentation and a focus on individual pathways will need to be done before a full picture of HNF-4α's role in the modulation of hepatic phenotype by injury can be obtained.
Cell culture and treatments
HepG2 cells (ATCC # HB-8065), human hepatoma cells, were grown in Dulbecco Modified Eagle Medium (DMEM) supplemented with penicillin (100 units/ml), streptomycin (100 μg/ml), and 10% heat-inactivated fetal bovine serum (Mediatech, Herndon, VA) at 37°C in a humidified atmosphere with 5% CO2.
The inflammatory response in HepG2 cells was stimulated with a cytokine mixture consisting of 1 ng/ml of recombinant human IL-1β, 10 ng/ml of IL-6, and 10 ng/ml of TNF-α (PeproTech, Rocky Hill, NJ) in serum-free medium for 18 h.
Knock-down of HNF4α in HepG2 cells was carried out as described previously . Briefly, shRNA plasmids (HNF4α shRNA and non-specific control shRNA) were transfected into HepG2 cells with the Nucleofector (Amaxa Biosystem, Cologne, Germany) T-28 protocol following the manufacturer's instructions. Knock-down of ELK1 in HepG2 cells was performed by transfection with small interfering RNA (siRNA) (Ambion, Austin, TX) using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were placed in serum-free medium for 5 h and then either treated or untreated with cytokines for 18 h.
The different treated HepG2 cells were divided into four groups: Group 1, control: the cells were transfected with non-specific control shRNA; Group 2, HNF4α shRNA: the cells were transfected with HNF4α shRNA; Group 3, cytokines: the control cells were transfected with non-specific control shRNA and then treated with cytokines; Group 4, HNF4α shRNA with cytokine treatment: the cells were transfected with HNF4α shRNA prior to the treatment with cytokines. Four biological replicates from separate experiments were performed for each of the four study groups.
Total RNA isolation and real-time PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Quantitative real-time PCR analysis was conducted on the ABI 7000 Sequence Detection System and StepOnePlus™ Real-Time PCR System. Relative mRNA expression was quantified using the comparative Ct (ΔΔCt) method according to the ABI manual (Applied Biosystems, Foster City, CA). Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used in each reaction as an internal reference gene. Assays were performed in triplicate. TaqMan probes were used for the human HNF4α (Hs00230853_m1), complement component 5 (C5, Hs00156197_m1), lipopolysaccharide binding protein (LBP, Hs00188074_m1), serpin peptidase inhibitor member 3 (SERPINA3, Hs00153674_m1), complement component 4A (C4A, Hs00167147_m1), ELK1 (Hs00901847_m1), collagen, type IV, alpha 1 (COL4A1, Hs01007469_m1), zinc finger protein 175 (ZNF175, Hs00232535_m1), matrix metallopeptidase 15 (MMP15, Hs00233997_m1), SEC24 family, member A (SEC24A, Hs00405228_m1) and GAPDH (Hs99999905_m1) from the TaqMan®Gene Expression Assays (Applied Biosystems).
Affymetrix HG-U133A 2.0 GeneChips were used to study the expression levels for HepG2 cell RNA. Sample labeling, hybridization to microarrays, scanning and calculation of normalized expression levels were carried out at the Microarray Resource, Boston University School of Medicine, Boston, MA. RNA samples (four biological replicates for each of the four study groups: control, HNF4α shRNA, cytokines, and HNF4α shRNA with cytokine treatment) were analyzed. Microarray data were quantified and normalized using Affymetrix MicroArray Suite (MAS) 5.0. Two-way ANOVA analysis was then used to determine which probesets were differentially expressed between the untreated control and treated groups. Only probesets exhibiting differential expression with FDR < 0.01 were included in this study. After the ANOVA analysis was performed, K-means clustering was then used to cluster probesets that exhibit similar expression patterns within each category of differential expression. In order to eliminate multiple probesets, the raw data were clustered based on Unigene identifiers (ids), which represent unique transcription loci. Unigene ids associated with multiple probesets that exhibit different patterns of expression were removed from the dataset, ensuring unambiguous data that could be easily used in subsequent enrichment analyses. This approach ensures that, if anything, the results of subsequent analyses are conservative.
Gene ontology (GO) enrichment analysis
Before GO enrichment could be calculated, each GO annotation was mapped to a corresponding Unigene id. SwissProt ids associated with each Unigene id were obtained and were used for this purpose. Where SwissProt ids were not available, gene symbols were used to associate GO annotations with Unigene ids. Each cluster in all 4 categories was then tested for enrichment for genes associated with inflammatory response GO database (relative to the entire set of genes on the microarray) using Fisher's Exact test. In addition, to identify other functionality, each cluster was tested for enrichment of each of the top-level "biological process" annotations in the GO database. As there are 26 top-level "biological process", a Bonferroni correction was applied for this top-level analysis, resulting in a p-value cut-off of 0.002.
Weight matrices obtained from the JASPAR core database  were used to identify potential transcription factor binding sites in the up-stream of promoter regions. One promoter with each Unigene id was included in the analysis, so that genes with multiple annotated promoters/TSS did not bias the analysis. The region, extending from -1 kb to +0.5 kb relative to the TSS, was extracted. Clover  was used with a minimum log-ratio score cut-off of 8.0 to identify potential binding sites in this region. Promoters were classified based on whether they contain at least one binding site, and enrichment in different expression clusters relative to a background set of promoters derived from all probesets present on the microarray. The randomization feature of Clover was not used, instead the exact number of promoters containing binding sites in both the HNF4α-regulated set and the background set were computed, and a p-value was calculated using Fisher's Exact test. Because there are almost 140 transcription factors in the JASPAR database, a Bonferroni correction was applied, resulting in a p-value cut-off of 3.5 × 10-4.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously . The purified chromatin was immunoprecipitated using 10 μg of anti-HNF-4α (sc-6556, Santa Cruz Biotechnology, Santa Cruz, CA) or normal goat IgG (Santa Cruz). After DNA purification, the presence of the ELK1 putative binding motif (CCGGAAG/A) DNA sequence was assessed by PCR. The primers used were as follows: (1) COL4A1 gene: 5'-GAGTTTAGCGCAGGATGAGG-3' and 5'-GCTCTCCTGCTTGGGAGTAG-3', and the PCR product is 230 bp in length; (2) ZNF175: 5'-TAAAAGCCCTTTGACGATGG-3' and 5'-CTCTAGGCCACTTCCGGTTT-3', and the PCR product is 239 bp in length; (3) MMP15: 5'-ATCCAGCTCGTTAAGCTTCG-3' and 5'-TTAATCTCTCCGAGCCTCCA-3' for amplifying a 207 bp DNA fragment. (4) SEC24A: 5'-GCACCAGGAGCTGTCAGG-3' and 5'-GGCAGCCAAACCTAGAGAGA-3', and the PCR product is 186 bp in length. The PCR conditions were as following: 95°C for 10 min, followed by 94°C for 45 s, 58°C for 60 s, and 72°C for 60 s for a total of 31 cycles. In the ELK1 knock-down experiments, the relative quantitative analysis in binding activity was performed, utilizing densitometry and statistical analysis, by comparison of siELK1 with non-specific siRNA control, and the control was set at 1.
This work was supported by NIH grant (R01DK064945). The authors wish to thank the Microarray Resource, Boston University School of Medicine, Boston, MA for performing the microarray experiments and for help with data analysis. We also thank Dr. Marc Lenburg and Dr. Avrum Spira for critical reading of the manuscript.
- Costa RH, Kalinichenko VV, Holterman AX, Wang X: Transcription factors in liver development, differentiation, and regeneration. Hepatology. 2003, 38 (6): 1331-1347.View ArticlePubMedGoogle Scholar
- Wiwi CA, Waxman DJ: Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors. 2004, 22 (2): 79-88. 10.1080/08977190410001715172.View ArticlePubMedGoogle Scholar
- Cheung C, Akiyama TE, Kudo G, Gonzalez FJ: Hepatic expression of cytochrome P450 s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem Pharmacol. 2003, 66 (10): 2011-2020. 10.1016/S0006-2952(03)00586-0.View ArticlePubMedGoogle Scholar
- Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, Roskams T, Rousseau GG, Lemaigre FP: The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development. 2002, 129 (8): 1819-1828.PubMedGoogle Scholar
- Shih DQ, Navas MA, Kuwajima S, Duncan SA, Stoffel M: Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3alpha-deficient mice. Proc Natl Acad Sci USA. 1999, 96 (18): 10152-10157. 10.1073/pnas.96.18.10152.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, Taylor LR, Wilson DR, Darlington GJ: Impaired energy homeostasis in C/EBP alpha knockout mice. Science. 1995, 269 (5227): 1108-1112. 10.1126/science.7652557.View ArticlePubMedGoogle Scholar
- Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, Bachvarova RF, Darnell JE: Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 1994, 8 (20): 2466-2477. 10.1101/gad.8.20.2466.View ArticlePubMedGoogle Scholar
- Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ: Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001, 21 (4): 1393-1403. 10.1128/MCB.21.4.1393-1403.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Hanniman EA, Lambert G, Inoue Y, Gonzalez FJ, Sinal CJ: Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha. J Lipid Res. 2006, 47 (11): 2503-2514. 10.1194/jlr.M600303-JLR200.View ArticlePubMedGoogle Scholar
- Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Bjorkhem I, et al: Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res. 2006, 47 (1): 215-227. 10.1194/jlr.M500430-JLR200.View ArticlePubMedGoogle Scholar
- Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, et al: Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem. 2006, 281 (8): 5246-5257. 10.1074/jbc.M507496200.View ArticlePubMedGoogle Scholar
- Ryffel GU: Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J Mol Endocrinol. 2001, 27 (1): 11-29. 10.1677/jme.0.0270011.View ArticlePubMedGoogle Scholar
- Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al: Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004, 303 (5662): 1378-1381. 10.1126/science.1089769.View ArticlePubMedPubMed CentralGoogle Scholar
- Baumann H, Gauldie J: The acute phase response. Immunol Today. 1994, 15 (2): 74-80. 10.1016/0167-5699(94)90137-6.View ArticlePubMedGoogle Scholar
- Beal AL, Cerra FB: Multiple organ failure syndrome in the 1990 s. Systemic inflammatory response and organ dysfunction. Jama. 1994, 271 (3): 226-233. 10.1001/jama.271.3.226.View ArticlePubMedGoogle Scholar
- Cerra FB: The systemic septic response: concepts of pathogenesis. J Trauma. 1990, 30 (12 Suppl): S169-174.PubMedGoogle Scholar
- Herbst RS, Nielsch U, Sladek F, Lai E, Babiss LE, Darnell JE: Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. New Biol. 1991, 3 (3): 289-296.PubMedGoogle Scholar
- Li X, Salisbury-Rowswell J, Murdock AD, Forse RA, Burke PA: Hepatocyte nuclear factor 4 response to injury involves a rapid decrease in DNA binding and transactivation via a JAK2 signal transduction pathway. Biochem J. 2002, 368 (Pt 1): 203-211. 10.1042/BJ20020233.View ArticlePubMedPubMed CentralGoogle Scholar
- Burke PA, Drotar M, Luo M, Yaffe M, Forse RA: Rapid modulation of liver-specific transcription factors after injury. Surgery. 1994, 116 (2): 285-292. discussion 292-283PubMedGoogle Scholar
- Burke PA, Luo M, Zhu J, Yaffe MB, Forse RA: Injury induces rapid changes in hepatocyte nuclear factor-1: DNA binding. Surgery. 1996, 120 (2): 374-380. 10.1016/S0039-6060(96)80312-6. discussion 380-371View ArticlePubMedGoogle Scholar
- Wang Z, Burke PA: Effects of hepatocyte nuclear factor-4alpha on the regulation of the hepatic acute phase response. J Mol Biol. 2007, 371 (2): 323-335. 10.1016/j.jmb.2007.05.049.View ArticlePubMedPubMed CentralGoogle Scholar
- Perlmutter DH, May LT, Sehgal PB: Interferon beta 2/interleukin 6 modulates synthesis of alpha 1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest. 1989, 84 (1): 138-144. 10.1172/JCI114133.View ArticlePubMedPubMed CentralGoogle Scholar
- Knowles BB, Howe CC, Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980, 209 (4455): 497-499. 10.1126/science.6248960.View ArticlePubMedGoogle Scholar
- Ganapathi MK, May LT, Schultz D, Brabenec A, Weinstein J, Sehgal PB, Kushner I: Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun. 1988, 157 (1): 271-277. 10.1016/S0006-291X(88)80043-3.View ArticlePubMedGoogle Scholar
- Bartalena L, Farsetti A, Flink IL, Robbins J: Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Mol Endocrinol. 1992, 6 (6): 935-942. 10.1210/me.6.6.935.PubMedGoogle Scholar
- Baumann H, Richards C, Gauldie J: Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol. 1987, 139 (12): 4122-4128.PubMedGoogle Scholar
- Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA. 1987, 84 (20): 7251-7255. 10.1073/pnas.84.20.7251.View ArticlePubMedPubMed CentralGoogle Scholar
- Shaw PE, Saxton J: Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int J Biochem Cell Biol. 2003, 35 (8): 1210-1226. 10.1016/S1357-2725(03)00031-1.View ArticlePubMedGoogle Scholar
- Sharrocks AD: Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture. Biochem Soc Trans. 2002, 30 (2): 1-9. 10.1042/BST0300001.View ArticlePubMedGoogle Scholar
- Naiki T, Nagaki M, Shidoji Y, Kojima H, Imose M, Kato T, Ohishi N, Yagi K, Moriwaki H: Analysis of gene expression profile induced by hepatocyte nuclear factor 4alpha in hepatoma cells using an oligonucleotide microarray. J Biol Chem. 2002, 277 (16): 14011-14019. 10.1074/jbc.M105403200.View ArticlePubMedGoogle Scholar
- Stanulovic VS, Kyrmizi I, Kruithof-de Julio M, Hoogenkamp M, Vermeulen JL, Ruijter JM, Talianidis I, Hakvoort TB, Lamers WH: Hepatic HNF4alpha deficiency induces periportal expression of glutamine synthetase and other pericentral enzymes. Hepatology. 2007, 45 (2): 433-444. 10.1002/hep.21456.View ArticlePubMedGoogle Scholar
- Rodriguez JC, Ortiz JA, Hegardt FG, Haro D: The hepatocyte nuclear factor 4 (HNF-4) represses the mitochondrial HMG-CoA synthase gene. Biochem Biophys Res Commun. 1998, 242 (3): 692-696. 10.1006/bbrc.1997.8032.View ArticlePubMedGoogle Scholar
- Sladek FM, Zhong WM, Lai E, Darnell JE: Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990, 4 (12B): 2353-2365. 10.1101/gad.4.12b.2353.View ArticlePubMedGoogle Scholar
- Frith MC, Fu Y, Yu L, Chen JF, Hansen U, Weng Z: Detection of functional DNA motifs via statistical over-representation. Nucleic Acids Res. 2004, 32 (4): 1372-1381. 10.1093/nar/gkh299.View ArticlePubMedPubMed CentralGoogle Scholar
- Rada-Iglesias A, Wallerman O, Koch C, Ameur A, Enroth S, Clelland G, Wester K, Wilcox S, Dovey OM, Ellis PD, et al: Binding sites for metabolic disease related transcription factors inferred at base pair resolution by chromatin immunoprecipitation and genomic microarrays. Hum Mol Genet. 2005, 14 (22): 3435-3447. 10.1093/hmg/ddi378.View ArticlePubMedGoogle Scholar
- Smith AD, Sumazin P, Das D, Zhang MQ: Mining ChIP-chip data for transcription factor and cofactor binding sites. Bioinformatics. 2005, 21 (Suppl 1): i403-412. 10.1093/bioinformatics/bti1043.View ArticlePubMedGoogle Scholar
- Reddy S, Yang W, Taylor DG, Shen X, Oxender D, Kust G, Leff T: Mitogen-activated protein kinase regulates transcription of the ApoCIII gene. Involvement of the orphan nuclear receptor HNF4. J Biol Chem. 1999, 274 (46): 33050-33056. 10.1074/jbc.274.46.33050.View ArticlePubMedGoogle Scholar
- Hatzis P, Kyrmizi I, Talianidis I: Mitogen-activated protein kinase-mediated disruption of enhancer-promoter communication inhibits hepatocyte nuclear factor 4alpha expression. Mol Cell Biol. 2006, 26 (19): 7017-7029. 10.1128/MCB.00297-06.View ArticlePubMedPubMed CentralGoogle Scholar
- Li QJ, Vaingankar S, Sladek FM, Martins-Green M: Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. Blood. 2000, 96 (12): 3696-3706.PubMedGoogle Scholar
- Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, Evans JR, Jiang T, Sladek FM: Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology. 2010, 51 (2): 642-653.View ArticlePubMedPubMed CentralGoogle Scholar
- Li R, Pei H, Watson DK: Regulation of Ets function by protein-protein interactions. Oncogene. 2000, 19 (55): 6514-6523. 10.1038/sj.onc.1204035.View ArticlePubMedGoogle Scholar
- Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B: JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004, D91-94. 10.1093/nar/gkh012. 32 DatabaseGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.